<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110522</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00117215</org_study_id>
    <nct_id>NCT04110522</nct_id>
  </id_info>
  <brief_title>Psoriatic Arthritis D2P Screening</brief_title>
  <official_title>Accelerating Psoriatic Arthritis Detection in Patients With Psoriasis: Direct-to-patient Administration of Screening Questionnaires (D2P Screening)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessica Walsh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this study is to develop a direct-to-patient screening approach that
      will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously
      developed screening questionnaires were intended for use in the setting of a doctor's office
      to assist providers with referral decisions. However, these screening questionnaires are
      infrequently used in routine practice because of limitations with time and resources. The
      study will aim to develop a practical screening strategy that does not require involvement
      from dermatologists (or other non-rheumatology providers) and can systematically reach a
      broad range of psoriasis patients, including patients not attending dermatology clinics. The
      researchers hypothesize that disseminating questionnaires directly to patients outside of a
      clinic setting (direct-to-patient approach) will educate patients about their PsA risk and
      improve early PsA diagnoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electronic medical record (EMR) systems will be used to identify psoriasis patients without a
      PsA diagnosis. Patients will be randomized to receive a PsA screening questionnaire
      (intervention group) or not receive a questionnaire (control group). Rates of rheumatologic
      evaluations and new PsA diagnoses will be compared between the groups, using EMRs to
      longitudinally track outcomes.

      Intervention group patients who through the completion of the PsA Screening questionnaire
      positively self-screen for an elevated PsA risk will either be randomly invited to directly
      access a rheumatology appointment or instructed to talk with their doctor about a
      rheumatology referral. We will compare rates of rheumatologic evaluations and new PsA
      diagnoses between these groups to identify the best method for accessing rheumatology
      appointments.

      To determine if PsA patients diagnosed after receiving a screening questionnaire differ from
      patients diagnosed via usual care; investigators will examine disease duration, severity, and
      comorbidities in patients receiving and not receiving the screening questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a new PsA diagnosis</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of psoriasis patients with a new diagnosis of PsA will be compared between the Experimental Arms and the Control Arm, and compared between the two Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom duration</measure>
    <time_frame>6 months</time_frame>
    <description>Average duration of baseline symptoms prior to PsA diagnosis in the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) will be compared to the average duration of baseline symptoms prior to PsA diagnosis in the Control Arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who complete a rheumatologic evaluation</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of psoriasis patients who complete a rheumatologic evaluation will be compared between the Experimental Arms and the Control Arm, and compared between the two Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initial PsA diagnosis after questionnaire dissemination</measure>
    <time_frame>6 months</time_frame>
    <description>The average time to PsA diagnosis after dissemination of the questionnaire in the Intervention with Direct Access to Rheumatologist arm compared to the Intervention with Standard of Care Referral Arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rheumatologic evaluation after questionnaire dissemination</measure>
    <time_frame>6 months</time_frame>
    <description>The average time to rheumatologic evaluation after dissemination of the questionnaire in the Intervention with Direct Access to Rheumatologist arm compared to the Intervention with Standard of Care Referral Arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of PsA Disability</measure>
    <time_frame>6 months</time_frame>
    <description>Average work disability in PsA, as measured by the Work Productivity and Activity Impairment questionnaire score will be compared between the Experimental ams (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function level in PsA</measure>
    <time_frame>6 months</time_frame>
    <description>Average physical function level in PsA, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) questionnaire score will be compared between the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of PsA radiographic damage</measure>
    <time_frame>6 months</time_frame>
    <description>Average number of psoriatic arthritis inflammatory changes per rheumatology provider's judgement after review of all relevant available imaging data using scale of yes/no/unsure will be compared between the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PsA Activity by Joint Count</measure>
    <time_frame>6 months</time_frame>
    <description>Average number of swollen/tender joints in PsA using the 66/68 joint count assessment by rheumatology provider physical exam will be compared between the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PsA Activity by Enthesitis</measure>
    <time_frame>6 months</time_frame>
    <description>Average number of joint insertions with enthesitis in PsA as determined by the Leeds enthesitis index as assessed by rheumatology provider physical exam will be compared between the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PsA Activity by Dactilitis Count</measure>
    <time_frame>6 months</time_frame>
    <description>Average number of digits with dactylitis in PsA using a dactylitis count (yes/no for each finger or toe) as assessed by rheumatology provider physical exam will be compared between the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) and the Control Arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Intervention with Direct Access to Rheumatologist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention with Standard of Care Referral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct to patient PsA Screening Questionnaire</intervention_name>
    <description>Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST â‰¥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.</description>
    <arm_group_label>Intervention with Direct Access to Rheumatologist</arm_group_label>
    <arm_group_label>Intervention with Standard of Care Referral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an International Classification of Diseases (ICD) code diagnosis of psoriasis but
             without a confirmed diagnosis of Psoriatic Arthritis prior to study initiation

          -  Be age 18 or older

          -  Be geographically located within a reasonable proximity to the Rheumatology study site

        Exclusion Criteria:

          -  Have psoriasis and a confirmed diagnosis of psoriatic arthritis made or confirmed by a
             rheumatologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Walsh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Walsh, M.D.</last_name>
    <phone>801-581-4333</phone>
    <email>jessica.walsh@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Ogdie, M.D.</last_name>
      <phone>215-662-2454</phone>
    </contact>
    <investigator>
      <last_name>Alexis Ogdie, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Ibrahim</last_name>
      <phone>801-581-8300</phone>
      <email>sonia.ibrahim@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Walsh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Jessica Walsh</investigator_full_name>
    <investigator_title>Assistant Professor, Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

